Foundayo and Wegovy: New Oral GLP-1 Medications Offer Weight Loss Options
The landscape of weight management medications has expanded with the approval of oral GLP-1 drugs, Foundayo (orforglipron) and Wegovy (semaglutide). Both medications work by mimicking the natural hormone GLP-1, which signals fullness, slows gastric emptying, regulates insulin, and suppresses glucagon, leading to reduced food intake and weight loss. While both are effective, they differ in dosing schedules, drug interactions, and clinical data. Oral Wegovy requires a stricter routine, taken on an empty stomach with water, followed by a 30-minute wait before eating or drinking. Foundayo offers more flexibility, as it can be taken anytime with or without food. Both carry a boxed warning for thyroid C-cell tumors, based on rodent studies, and are contraindicated for individuals with a history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Common side effects for both are primarily digestive, peaking early in treatment.
